Hansoh Pharmaceutical (03692.HK): Fourth NDA for Ameile® (Almonertinib Mesylate Tablets) Accepted by China's NMPA

Hansoh Pharma (03692) announced that the fourth New Drug Application (NDA) for its innovative drug Almonertinib Mesylate Tablets (brand name: Amelie®), developed by its subsidiary Jiangsu Hansoh Pharmaceutical Group Co., Ltd., has been accepted by the National Medical Products Administration (NMPA) of China. The application is for the treatment of patients with unresectable, locally advanced non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and have not experienced disease progression after platinum-based radical chemoradiotherapy.